LEADER 04618nam 2200985z- 450 001 9910557306103321 005 20210501 035 $a(CKB)5400000000042795 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69346 035 $a(oapen)doab69346 035 $a(EXLCZ)995400000000042795 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCellular and Molecular Mechanisms in Pathogenesis of Multiple Sclerosis 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (182 p.) 311 08$a3-03943-555-8 311 08$a3-03943-556-6 330 $aMultiple sclerosis (MS) is one of the most common neurological disorders in young adults. The etiology of MS is not known, but it is generally accepted that it is autoimmune in nature. Our knowledge of the pathogenesis of MS has increased tremendously in the past decade through clinical studies and the use of experimental autoimmune encephalomyelitis (EAE), a model that has been widely used for MS research. Major advances in the field, such as understanding the roles of pathogenic Th17 cells, myeloid cells, and B cells in MS/EAE, as well as cytokine and chemokine signaling that controls neuroinflammation, have led to the development of potential and clinically approved disease-modifying agents (DMAs). There are many aspects related to the initiation, relapse and remission, and progression of MS that are yet to be elucidated. For instance, what are the genetic and environmental risk factors that promote the initiation of MS, and how do these factors impact the immune system? What factors drive the progression of MS, and what are the roles of peripheral immune cells in disease progression? How do the CNS-infiltrated immune cells interact with the CNS-resident glial cells when the disease progresses? What is the role of microbiome in MS? Can we develop animal models that better represent subcategories of MS? Understanding the cellular and molecular mechanisms that govern the pathogenesis of MS will help to develop novel and more specific therapeutic strategies that will ultimately improve clinical outcomes of the treatments. This Special Issue of Cells has published original research articles, a retrospective clinical report, and review articles that investigate the cellular and molecular basis of MS. 606 $aMedicine and Nursing$2bicssc 610 $aA971432 610 $aautoimmune disease 610 $aAUY954 610 $abioinformatics 610 $aCD4+ T cells 610 $acentral memory T cell 610 $aclonal analyses 610 $ademyelination 610 $adisease activity 610 $aeffector memory T cell 610 $aexperimental autoimmune encephalomyelitis 610 $aexperimental autoimmune encephalomyelitis (EAE) 610 $agliosis 610 $aglutamate synaptic dysfunction 610 $agranulocyte-macrophage colony-stimulating factor 610 $ahistology 610 $aIDO 610 $ain utero electroporation 610 $ainside-out 610 $akynurenic acid 610 $akynurenine pathway 610 $alaquinimod 610 $alesioned brain 610 $alineage 610 $alymphocytes 610 $amemory T cells 610 $amicroglia 610 $amitochondria 610 $amonocytes 610 $amorphometric analyses 610 $amultiple sclerosis 610 $aN-acetylserotonin 610 $an/a 610 $aNAD+, multiple sclerosis 610 $aneuroinflammation 610 $aneutrophils 610 $aNG2-glia 610 $aNLR 610 $aoligodendrocytosis 610 $aoutside-in 610 $aoxidative stress 610 $aozanimod 610 $apentamidine 610 $apro-inflammatory cytokines 610 $aprogenitors 610 $aquinolinic acid 610 $arelapsing-remitting experimental autoimmune encephalomyelitis 610 $aS100B 610 $aS1P1 610 $aS1P5 610 $asphingosine-1-phosphate receptors 610 $aT lymphocytes 610 $atissue-resident T cell 610 $atop-down proteomics 615 7$aMedicine and Nursing 700 $aWan$b Edwin$4edt$01303362 702 $aWan$b Edwin$4oth 906 $aBOOK 912 $a9910557306103321 996 $aCellular and Molecular Mechanisms in Pathogenesis of Multiple Sclerosis$93026946 997 $aUNINA